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FGF23refers to a group of disorders inherited in an autosomal recessive fashion.
Hyperphosphatemic tumoral calcinosis is characterized by increased re-absorption of phosphate through the
renal proximal tubule, resulting in elevated phosphate concentration and deposition of calciﬁed deposits in
cutaneous and subcutaneous tissues, as well as, occasionally, in visceral organs. The disease was found to
result from mutations in at least 3 genes: GALNT3, encoding a glycosyltransferase termed ppGalNacT3, FGF23
encoding a potent phosphaturic protein, and KL encoding Klotho. Recent data showed that ppGalNacT3
mediates O-glycosylation of FGF23, thereby allowing for its secretion and possibly protecting it from
proteolysis-mediated inactivation. Klotho was found to serve as a co-receptor for FGF23, thereby integrating
the genetic data into a single physiological system. The elucidation of the molecular basis of HFTC shed new
light upon the mechanisms regulating phosphate homeostasis, suggesting innovative therapeutic strategies
for the management of hyperphosphatemia in common acquired conditions such as chronic renal failure.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionExtraosseous calciﬁcation (calciﬁcation occurring in non-osseous
tissues) is awell-known complication ofmany common disorders such
as chronic renal failure or hyperparathyroidismwhich has been shown
to predict morbidity and mortality in the general population. [1–5].
Thus, much effort has been invested in an attempt to delineate the
mechanisms responsible formaintaining normal circulating phosphate
levels. The study of rare monogenic disorders can be instrumental in
the discovery of novel physiological pathways [6]. As reviewed in the
present article, the deciphering of the molecular basis of familial
tumoral calcinosis (FTC) illustrates remarkably well this paradigm.
2. Familial tumoral calcinosis: (at least) two distinct
metabolic phenotypes
Calcinosis refers to the ectopic (non-osseous) deposition of
calcium salts [7]. Cutaneous calcinosis is a relatively common clinical
occurrence, reported in diseases as common as chronic renal failure,
atherosclerosis, acne, cancer and autoimmune diseases [8]. Hereditary
idiopathic calcinosis, known as FTC, was ﬁrst described more than a
century ago by Giard [8]. The exact prevalence rate of FTC is unknown;
however, the disease has been mainly reported in patients of Middley Tel Aviv Sourasky Medical
r).
ll rights reserved.Eastern or African ancestry [9]. All forms of FTC are transmitted in an
autosomal recessive fashion [10]. Two major FTC types have been
described: hyperphosphatemic FTC (HFTC; MIM211900), the topic of
the present review, which is characterized by marked and persistent
hyperphosphatemia leading to the development of large periarticular
calciﬁedmasses, weighing up to 1 kg [11,12]; and normophosphatemic
FTC (NFTC; MIM610455), featuring smaller calciﬁed masses often
located at pressure points but not only [10,13,14]. Visceral calciﬁcation
can accompany HFTC [15] while it has never been reported in NFTC. In
both forms of FTC, renal function is normal. However, in HFTC,
intestinal and renal tubular phosphate re-absorption is increased in
the face of inappropriately normal levels of parathyroid hormone and
vitamin D metabolites, reﬂecting elevated activity of the major
inducible Na/Pi co-transporters, NaPiIIa-c [11,12,16–18]. In contrast,
the pathogenesis of ectopic calciﬁcation in NFTC is not associated with
metabolic abnormalities. Here, the disease seems to result from
aberrant regulation of inﬂammation, as attested by the fact that a
vasculitis-like rash often precedes tumor formation [10,13].
3. Molecular genetics of FTC
The genetic etiopathogenesis of FTC started to unfold through the
study of a large and highly consanguineous kindred of Druze origin
affected with HFTC [10]. The Druzes constitute a small ethnic minority
of Arab Moslem origin which assembled in Egypt about half a
millennium ago and live today in mountainous areas of the Near East
[19]. This population is highly inbred due to the fact that marriages
Table 1
Mutation spectrum in FTC.
Hyperphosphatemic familial tumoral calcinosis
Gene Nucleotide change Predicted consequence Reference
GALNT3 c.484CNT c.1524+5GNA p.R162X Splicing error [22]
GALNT3 c.1524+1GNA p.K465_Y508del [22]
GALNT3 c.484CNT c.516-2ANT p.R162X Splicing error [82]
GALNT3 c.815 CNA c.1076 CNA p.T272K p.T359K [43]
GALNT3 c.1774 CNT Q592X [83]
GALNT3 c.41-58del Protein truncation [66]
GALNT3 C1387 ANT K463X [87]
GALNT3 966TNG 1441CNT Y322X Q481X [88]
GALNT3 c.1102_1103insT E375X [84]
GALNT3 1460 GNA W487X [84]
GALNT3 C.516-2A NT Splicing error [85]
FGF23 c.211ANG p.S71G [50]
FGF23 c.211ANG p.S71G [51]
FGF23 c. 386CNT p.S129F [49]
FGF23 c.287TNC p.M96T [15]
FGF23 c.160CNA p. Q54K [52]
Klotho c.578 ANG p. H193R [53]
Hyperostosis hyperphosphatemia syndrome
Gene Nucleotide change Predicted amino acid change Reference
GALNT3 c. 1524+1GNA p.K465_Y508del [24]
GALNT3 c. 803-804insC c. 1626+1GNA E271X exon 8 splice site [25]
GALNT3 c. 1584 GNA p. R438H [26]
Normophosphatemic familial tumoral calcinosis
Gene Nucleotide change Predicted amino acid change Reference
SAMD9 c.4483ANG p.K1495E [56]
SAMD9 c. 1031CNT R344X [57]
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is not allowed [20]. Rare recessive diseases affecting inbred popula-
tions are often caused by homozygous mutations, a fact that forms the
theoretical basis for a powerful approach to gene localization, termed
homozygosity mapping [21]. Using this technique, a splice site
mutation in a gene called GALNT3 was found to segregate with the
disease in the affected kindred [22]. Since then, 10 distinct mutations
have been identiﬁed in families of various origins (Table 1). These
mutations have been predicted and, in speciﬁc cases, shown, to result
in loss of protein expression [23].
Of interest, mutations in GALNT3 were also found to underlie a
bone disease, called hyperphosphatemic hyperostosis syndrome
(HHS) [24–26]. Like HFTC, HHS is transmitted in an autosomal
recessive fashion and is characterized by hyperphosphatemia [27–31].
The disease manifests with paroxysmal episodes of excruciating pain
along the long bones, associated with radiographic evidence of
hyperostosis. In one single instance, a founder mutation was found
to cause HHS in one ethnic subgroup and HFTC in another [24],
strongly suggesting the importance of modiﬁer traits in determining
the ﬁnal expression of deleterious mutations in GALNT3.Table 2
Phosphate transporters and their diseases.
Protein
names
Gene Expression site Dise
NaPi-I, NPT1 SLC17A1 Kidney, liver
NaPi-IIa SLC34A1 Kidney (proximal tubules; apical) osteoclasts, neurons Nep
NaPi-IIb SLC34A2 Small intestine, lung, testis, liver, secreting mammary gland Pulm
NaPi-IIc SLC34A3 Kidney (proximal tubules, apical) Here
(MIM
Pit-1 Glvr-1 SLC20A1 Ubiquitous
Pit-2 Glvr-2 SLC20A2 UbiquitousGALNT3 encodes UDP-N-acetyl-α-d-galactosamine:polypeptide
n-acetylgalactosaminyl transferase 3 (ppGalNacT3), one out of 24
members of a family of glycosyltransferases responsible for initiating
O-glycosylation [32]. Apart from HFTC and HHS, no other human
disease has so far been linked to this group of proteins. Soon after the
discovery of mutations in GALNT3 as the proximal cause of HFTC, it
appeared that many individuals displaying typical features of HFTC do
not carry mutations in this gene. This observation led a number of
investigators to assess other candidate genes of potential relevance to
the maintenance of normal circulating levels of phosphate. Circulating
phosphate levels are determined by a balance between dietary intake,
incorporation in bone and other tissues, and excretion through urine
and stool [17,18,33–35]. A large number of Na+-dependent phosphate-
co-transporters are involved in phosphate handling. They have been
classiﬁed into three different families: type I (SLC17), type II (SLC34)
and type III (SLC20). The type II transporters (NaPiIIa, NaPiIIb, and
NaPiIIc) are subject to tight regulation and are responsible for the
majority of Pi re-absorption in polarized cells. NapiIIb transporter is
expressed in the small intestine, lung, mammary glands, testis, and
liver [36] and is involved in transcellular transport of phosphate in the
small intestine [37]. The NaPiIIa and NaPiIIc transporters are expressed
almost exclusively in kidneyand control renal phosphate re-absorption
[38]. Genetic defects have described for each of these transporters:
mutations in SLC34A1, coding forNaPiIIa,were reported in twopatients
with nephrolithiasis or osteoporosis accompanied by hypophosphate-
mia [39] although these observations are still of a controversial nature
[40]; mutations in SLC34A2 encoding NaPiIIb are associated with
pulmonary alveolar microlithiasis (MIM265100); and mutations
affecting NaPiIIc function cause hereditary hypophosphatemic rickets
with hypercalciuria (HHRH; MIM241530) [41–44]. Although parathyr-
oid hormone and vitamin D3 are potent regulators of phosphate blood
levels [33], the fact that they primarily affect calcium homeostasis had
suggested the existence of other circulating factors speciﬁcally
involved in the regulation of phosphate transport. These proteins,
known as phosphatonins [35], were discovered through the study of a
rare paraneoplastic condition, termed tumor-induced osteomalacia
[45], where tumor cells secrete factors increasing the renal excretion of
phosphate through the kidney. The best studied among these factors is
theﬁbroblast growth factor 23 (FGF23), which functions by decreasing
the expression of the renal phosphate transporter as well as de-
crease the 1alpha-hydroxylation and increase the (inactivating)
24-hydroxylation of vitamin D [16,46] (Table 2). Gain-of-function
mutations in the FGF23 gene were found to cause dominant hypopho-
sphatemic rickets (MIM193100), a disorder characterized by increased
renal tubular excretion of phosphate and bone mass loss [18,47]. Since
this disease represents in many aspects the metabolic mirror image of
HFTC, some authors [35,48] raised the possibility thatHFTCmayalso be
related to defective FGF23 function. And indeed, a year after the
identiﬁcation of mutations in GALNT3, a number of laboratories
reported loss-of-function in FGF23 in patients displaying typical HFTC
features [15,49–52]. Thesemutationswere found to result in decreased
FGF23 stability and/or decreased secretion, as well as reduced (but not
absent) activity of FGF23. Finally, a case of atypical HFTC, characterizedase (OMIM) References
hrolithiasis or osteoporosis (MIM612286) [39]
onary alveolar microlithiasis (MIM265100) [86]
ditary hypophosphatemic rickets with hypercalciuria HHRH;
241530)
[41–43]
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long bones and skull, intracranial calciﬁcations associated with
hyperphosphatemia, hypercalcemia and high PTH levels, was found
to result from a deleterious mutation in KL [53], encoding Klotho, a
molecule previously related inmice to senescence [54]. Interestingly, a
gain-of-function translocation involving the same gene was shown to
cause a reverse phenotype consisting of hypophosphatemic rickets and
hyperparathyroidism [55].
As mentioned above, distinctive features seem to demarcate
clinically NFTC and HFTC [56]. Accordingly NFTC was found to map
to a different locus than HFTC [22] and to result from mutations in a
gene termed SAMD9, which encodes a 1589 amino acid-long protein
of unknown function [56,57]. Given the rarity of NFTC and the fact that
the two mutations reported so far in SAMD9 have been exclusively
found in a very small ethnic subgroup, the Jewish Yemenite
population, it is very likely that the mutations arouse in this
population as a consequence of a selective effect of unknown nature
[57]. The two mutations reported so far in SAMD9 result in loss of
expression of this protein. Recent data suggest a role for SAMD9 in the
regulation of inﬂammation, apoptosis and cell proliferation [57,58]. In
agreement with these data, TNF-alpha induces SAMD9 expression in a
p38 and NFkB-dependant fashion [57].
4. Delineating a novel regulatory pathway through the
deciphering of the molecular basis of HFTC
The discovery of at least three genes carrying mutations causing
HFTC clearly suggests that the proteins encoded by these genes may
function along the same physiological pathway. As mentioned above,
ppGalNacT3, a galactosyltransferase encoded by GALNT3, is respon-
sible for initiating O-glycosylation usually on serine or threonine
residues. More than 20 different ppGalNacTs catalyze the initial
enzymatic step of mucin-type O-glycosylation [32]. In this reaction,
the monosaccharide N-acetylgalactosamine (GalNAc) is transferred to
the hydroxyl groups of serine and threonine residues [59]. Galactosyl-
transferases contain a short cytoplasmic tail, a transmembrane
domain, a stem region, a catalytic domain, and a C-terminal lectin
domain, unique to this family [60]. The expression of galactosyl-
transferases, including ppGalNacT3, has been shown to correlate with
prognosis in human cancers [61].
Despite the importance of mucin-type-O-glycosylation, as attested
by the high degree of conservation of galactosyltransferases throughout
evolution [62], HFTC is the only disease in humans known to be causedFig. 1. Role of ppGalNacT3, FGF23 and Klotho in the maintenance of phosphate homeostasis.
through proteolysis. Klotho serves as a co-receptor for FGF23. Accordingly, mutations in a
re-absorption and consequently, hyperphosphatemia with tumoral calcinosis.by mutations in a glycosyltransferase gene (although defective
galactosyltransferase activity due to impaired function of a speciﬁc
chaperone has been shown to cause a rare autoimmune disease called
Tn syndrome, which does not manifest clinically, but results in
abnormal laboratory ﬁndings including thrombocyto- and leukopenia
and some signs of hemolytic anemia not warranting any treatment
[63]). The very restricted phenotype associated with defective ppGal-
NacT3 function in humans is suggestive of functional redundancy in
tissues unaffected in HFTC. Similarly, mice deﬁcient in ppGalNacT1 only
demonstrate altered immune cell trafﬁcking, and moderate or severe
bleeding due to the fact that ppGalNAcT1 supports O-glycoprotein
expression among a subset of blood coagulation factors [24].
O-glycosylation of FGF23 was shown to be required for its proper
secretion in the extracellular milieu [64]. This, of course, immediately
raised the possibility that ppGalNacT3 could mediate FGF23 O-glyco-
sylation, a hypothesis that is supported by recent in vitro data [65].
ppGalNacT3 was found to selectively direct O-glycosylation of a
subtilisin-like proprotein convertase recognition sequence motif; O-
glycosylation of this motif results in inhibition of FGF23 proteolytic
degradation, pointing to a prime role for ppGalNacT3 in the regulation
of FGF23 activity [64]. Accordingly, FGF23 or GALNT3 mutations were
found to be associated with increased FGF23 proteolysis and
concomitantly decreased FGF23 activity [25,50,65,66]. Taken together,
these observations suggest that at least two different defects are
responsible for the high serum phosphate concentrations typically
found in HFTC and HHS: increased proteolysis of FGF23 due to FGF23
mutations, directly affecting protease recognition site(s), or decreased
ppGalNacT3-mediated O-glycosylation of these sites, with conse-
quently enhanced FGF23 susceptibility to proteolytic degradation.
Both processes result in decreased phosphaturia as a consequence of
decreased levels of active FGF23 activity. Decreased FGF23 activity
probably also underlies the pathogenesis of HFTC caused by
mutations in KL. Indeed, KL was found to encode Klotho. Klotho,
previously shown in mice to counteract aging in various systems [54],
is a multifunctional protein which has been shown to play a major
role in the maintenance of calcium homeostasis by inﬂuencing the
activity of the Na+, K+, ATPase pump, driving transepithelial calcium
transport, by affecting TRPV5 activity, but also by serving as an
essential element of FGF23-mediated signaling [67]. In man, the
protein was found to function as a co-receptor for FGF23, converting
FGF receptor 1 (IIIc) into a FGF23 receptor [68]. Thus decreased
activity of Klotho was also found to result in decreased phosphaturia
associated in this case with (possibly compensatory) elevated levelsppGalNacT3 mediates O-glycosylation of FGF23, thereby protecting it from degradation
nyone of these three genes, result in decreased FGF23 activity, increased phosphate
Fig. 2. Doxycycline up-regulates ppGalNacT3 expression in SaOs cells.
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with HFTC reveals the importance of a novel and pivotal regulatory
system responsible for maintaining normal circulating concentrations
of phosphate (Fig. 1), and therefore possibly involved in many
common acquired diseases as already exempliﬁed in a small number
of pioneering studies [69,70].
Despite these advances, a number of questions pertaining to the
physiological role of ppGalNacT3 remain open. In particular, the fact
that calcinosis in HFTC is often conﬁned to cutaneous and sub-
cutaneous tissues suggests that ppGalNacT3 deﬁciency may have a
speciﬁc effect on some regional elements in addition to its systemic
effect. GALNT3 is expressed ubiquitously [22], while FGF23 almost
exclusively originates from mineralized tissues [71]; these observa-
tions are in line with possible additional functions for ppGalNacT3 not
related to FGF23. Similarly, the wide range of symptoms manifested
by HFTC patients carrying (occasionally identical) loss-of-function
mutations in GALNT3, point to the existence of additional physiolo-
gical elements of importance in the regulation of phosphate home-
ostasis. It is in fact possible that ppGalNacT3 targets other molecules
than FGF23, also known to inﬂuence phosphate levels such as the
various phosphate co-transporters, other phosphatonins or PHEX or
DMP1, thought to regulate FGF23 synthesis [38]. Finally, although
FGF23 expression has been shown to be regulated by elements of
direct relevance to its role in phosphate metabolism [72,73], little is
currently known about the elements involved in the physiological
control of ppGalNacT3 activity.
5. Treatment of FTC
Given the rarity of the various types of FTC, very few data are
currently available regarding the best way to manage these very
disabling conditions. What even further adds to the difﬁculty in
interpreting the literature is the fact that many early papers did not
made the distinction between NFTC and HFTC. The recent data
reviewed above clearly indicate that although phenotypically similar,
the two diseases stems from completely different pathophysiological
defects. Logically, anti-inﬂammatory strategies should beneﬁt patients
affected with NFTC whereas in HFTC, effective treatment should be
designed to target the underlying metabolic defects.
A number of approaches have been tried over the years to treat
ectopic calciﬁcation, including laser therapy, the use of phosphate-
restricted diets, bisphosphonates, calcium channel blockers, corticos-
teroids, colchicines and chelating agents such as aluminium hydroxide
[74–77]. Inmost cases, results have been disappointingwith therapeutic
effects being either negligible or short-lasting. A recent report [52]
described a good response of a patientwithHFTC to a combinationof the
phosphate binding agent sevelamer with the carbonic anhydrase
inhibitor acetazolamide. Of interest, tetracyclines have been shown
occasionally to attenuate ectopic calciﬁcation [78–80]. A number of
hypotheses have been advanced to explain this effect including
inhibition ofmatrixmetalloproteinase activity, anti-inﬂammatoryeffect,
calcium binding or antibacterial action [78]. We were able to show that
doxycycline signiﬁcantly up-regulates ppGalNacT3 expression, suggest-
ing the need to assess the efﬁcacy of tetracyclines in HFTC (Fig. 2).
Interestingly, doxycyclinewas recently shown to exert a beneﬁcial effect
(unrelated to its antimicrobial activity) in a mouse model of Marfan
syndrome [81], possibly due to its inhibitory effect on MMP activity.6. Conclusion
The importance of the discovery of the genetic causes of HFTC and
NFTC goes much beyond the elucidation of the molecular basis of a
fascinating group of genetic diseases. As mentioned in the Introduc-
tion, extraosseous calciﬁcation has recently attracted much attention
because of the recognition of its contribution to morbidity and
mortality in the general population. Actually, two forms of ectopic
calciﬁcation have been recognized in humans: dystrophic calcinosis,
where ectopic calciﬁcation follows some form of tissue injury
(inﬂammation, cancer, vascular damage etc..) and metastatic calci-
nosis, which is always associated with an elevated calcium–phosphate
product in the circulation (as in renal failure or hyperparathyroidism)
[8]. At this regard, NFTC and HFTC nicely recapitulate most features of
these two forms of ectopic calciﬁcation, and consequently, represent
attractive models to design and test innovative therapies of potential
relevance to a wide range of common acquired diseases.
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